Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 523-528

  Cuisset, Thomas ^a,b,c   Gaborit, Bénédicte ^b,c,d   Dubois, Noémie ^a,c   Quilici, Jacques ^a,b,c   Loosveld, Marie ^a,b,c   Beguin, Shirley ^e   Loundou, Anderson Diendonné ^e   Moro, Pierre Julien ^a,c   Morange, Pierre Emmanuel ^a,b,c   Alessi, Marie Christine ^a,b,c   Dutour, Anne ^b,c,d   Bonnet, Jean Louis ^a,b,c  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CHU Nord   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Acute coronary syndrome; Clopidogrel; Platelet reactivity; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BLEEDING; BODY WEIGHT; CORONARY STENT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PLATELET REACTIVITY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT RESPONSE; WAIST CIRCUMFERENCE;

ACUTE CORONARY SYNDROME; CLOPIDOGREL; PLATELET REACTIVITY; PRASUGREL;

ACUTE CORONARY SYNDROME; AGED; BLOOD PLATELETS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84883812072     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.214     Document Type: Article

References (36)

1. K. Malmberg, S. Yusuf, and H.C. Gerstein Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry Circulation 102 2000 1014 1019
2. G. Anfossi, and M. Trovati Pathophysiology of platelet resistance to anti-aggregating agents in insulin resistance and type 2 diabetes: implications for anti-aggregating therapy Cardiovasc Hematol Agents Med Chem 4 2006 111 128
3. J.L. Ferreiro, and D.J. Angiolillo Diabetes and antiplatelet therapy in acute coronary syndrome Circulation 123 2011 798 813
4. P. Ferroni, S. Basili, A. Falco, and G. Davi Platelet activation in type 2 diabetes mellitus J Thromb Haemost 2 2004 1282 1291
5. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
6. T. Cuisset, C. Frere, and J. Quilici High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
7. T. Geisler, H. Langer, and M. Wydymus Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation Eur Heart J 27 2006 2420 2425
8. W. Hochholzer, D. Trenk, and H.P. Bestehorn Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 2006 1742 1750
9. P. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317
10. G. Campo, G. Parrinello, and P. Ferraresi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome J Am Coll Cardiol 57 2011 2474 2483
11. T. Cuisset, G. Cayla, and C. Frere Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
12. D. Sibbing, S. Schulz, and S. Braun Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
13. D.J. Angiolillo, E. Bernardo, and M. Sabaté Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547
14. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
15. S.D. Wiviott, E. Braunwald, and Angiolillo Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to assess Improvement in Therapeutic Outcomes by optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation 118 2008 1626 1636
16. D.J. Angiolillo, J.J. Badimon, and J.F. Saucedo A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial Eur Heart J 32 2011 838 846
17. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome Diabetes Metab 38 2012 113 127
18. U.R. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 1999 1145 1152
19. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
20. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
21. P. Roy, L. Bonello, and R. Torguson Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation Am J Cardiol 102 2008 1614 1617
22. S. Armero, L. Bonello, and J. Berbis Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes Am J Cardiol 108 2011 1710 1713
23. D. Soffer, I. Moussa, and K.J. Harjai Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 59 2003 21 25
24. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
25. T. Cuisset, C. Frere, and J. Quilici Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel non-responders: a prospective, randomized study JACC Cardiovasc Interv 1 2008 649 653
26. M. Valgimigli, G. Campo, and N. de Cesare Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 119 2009 3215 3222
27. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
28. L. Bonello, M. Pansieri, and J. Mancini High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
29. A.D. Michelson, A.L. Frelinger III, and E. Braunwald Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
30. Eur Heart J 32 2011 838 846
31. D. Alexopoulos, I. Xanthopoulou, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel Am Heart J 162 2011 733 739
32. G. Parodi, B. Bellandi, and F. Venditti Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel Am J Cardiol 109 2012 214 218
33. D. Aradi, W. Kuliczkowski, D. Atar, and V.L. Serebruany Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel Thromb Haemost 107 2012 338 345
34. C.T. Chin, M.T. Roe, and K.A. Fox Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial Am Heart J 160 2010 16 22 [e1]
35. C.W. Hamm, J.P. Bassand, and S. Agewall ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
36. G. Montalescot, L. Bolognese, and D. Dudek A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study Am Heart J 161 2011 650 656 [e1]